Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML

View Full Paper
Ask AI
Bookmark
Share

Authors

CGCarlo Gambacorti‐Passerini

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved molecular response in chronic myeloid leukemia patients, suggesting ponatinib and asciminib may reduce adverse events during treatment.

Key Points

  • All patients achieved molecular response by Day 28 without cytotoxic chemotherapy during treatment.
  • At 3 months, cytogenetic response varied, with improvements noted in bone marrow clearance among patients.
  • Treatment involved novel therapeutics ponatinib and asciminib administered to patients resistant to prior tyrosine kinase inhibitors.
  • Indicating potential benefits in pretransplant fitness, combination therapy helps reduce complications post allogeneic stem cell transplantation.

Cite This Study

Carlo Gambacorti‐Passerini (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbechttps://doi.org/10.1182/blood-2025-7301
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase2025
  2. 2Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  3. 3Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study2025
  4. 4A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase2025
  5. 5COMPARATIVE EFFICACY AND SAFETY OF NEW-GENERATION TYROSINE KINASE INHIBITORS IN ACHIEVING DEEP MOLECULAR REMISSION AND REMISSION WITHOUT TREATMENT IN CHRONIC MYELOID LEUKEMIA2025